Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).
Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S. Gumbleton M, et al. Among authors: burnett w. BMC Res Notes. 2023 Feb 16;16(1):16. doi: 10.1186/s13104-023-06283-5. BMC Res Notes. 2023. PMID: 36797744 Free PMC article. Clinical Trial.
AKT1 Activation Promotes Development of Melanoma Metastases.
Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. Cho JH, et al. Among authors: burnett wj. Cell Rep. 2015 Nov 3;13(5):898-905. doi: 10.1016/j.celrep.2015.09.057. Epub 2015 Oct 22. Cell Rep. 2015. PMID: 26565903 Free PMC article.
Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression.
Parkman GL, Turapov T, Kircher DA, Burnett WJ, Stehn CM, O'Toole K, Culver KM, Chadwick AT, Elmer RC, Flaherty R, Stanley KA, Foth M, Lum DH, Judson-Torres RL, Friend JE, VanBrocklin MW, McMahon M, Holmen SL. Parkman GL, et al. Among authors: burnett wj. Mol Cancer Ther. 2024 Mar 4;23(3):301-315. doi: 10.1158/1535-7163.MCT-23-0474. Mol Cancer Ther. 2024. PMID: 37931033 Free PMC article.
Theranostics Using MCM-41-Based Mesoporous Silica Nanoparticles: Integrating Magnetic Resonance Imaging and Novel Chemotherapy for Breast Cancer Treatment.
Pires ICB, Shuchi SI, Tostes BVA, Santos DKDDN, Burnett WL, Leonce BC, Harvey OR, Coffer JL, de Sousa Filho IA, de Athayde-Filho PF, Junior SA, Mathis JM. Pires ICB, et al. Among authors: burnett wl. Int J Mol Sci. 2024 Jul 25;25(15):8097. doi: 10.3390/ijms25158097. Int J Mol Sci. 2024. PMID: 39125669 Free PMC article.
310 results